Adeno-associated virus type 2 (AAV) is a nonpathogenic human parvovirus which requires coinfection with a helper virus, such as adenovirus, for its optimal replication (3). In the absence of a helper virus, the wild-type AAV genome integrates in a site-specific way into human chromosome 19 and establishes a latent infection (14, 15, 27) . AAV possesses a wide host range that transcends the species barrier (18) . These properties of AAV have been instrumental in the development of recombinant AAV vectors for their use in human gene therapy (4-6, 18, 33-35, 40) . We and others have reported AAV-mediated transduction and transgene expression both in vitro and in vivo (1, 2, 9, 10, 12, 13, 17, 19-26, 28, 30, 41) . However, the transduction efficiency of AAV vectors varies greatly in different cell types. This problem has been attributed to the following two obstacles that AAV must overcome. First, AAV must bind to a cellular receptor as well as to a coreceptor for successful entry into the target cell (19, 21, 24, 36, 37) , and second, because AAV is a single-stranded DNA-containing virus, the target cell must allow for the conversion of the single-stranded viral genome to a transcriptionally active double-stranded intermediate (7, 8) . We have documented the existence of a host cell protein, which we have designated the single-stranded D sequence-binding protein (ssD-BP), which plays a crucial role in viral second-strand DNA synthesis (23, 25) . The ssD-BP is phosphorylated at tyrosine residues by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) activity, and the phosphorylated form of the ssD-BP prevents viral second-strand DNA synthesis and consequently AAV-mediated transgene expression (16) . In this report, we provide evidence for the existence of a third obstacle, impaired intracellular trafficking into the nucleus, which AAV must also overcome prior to high-efficiency transduction.
We recently documented that AAV binds to murine NIH 3T3 cells efficiently but that little transgene expression occurs (24) . This observation was interpreted as the inability of AAV to enter these cells. However, Southern blot analyses (31) of low-M r DNA isolated from NIH 3T3 cells soon after infection with a recombinant AAV vector containing the human cytomegalovirus (CMV) immediate-early gene promoter-driven bacterial ␤-galactosidase (lacZ) reporter gene revealed the presence of AAV single-stranded DNA. These results are shown in Fig. 1A . In these experiments, equivalent numbers of Raji (nonpermissive for AAV binding and entry) (24) , 293 (permissive for viral binding and entry) (23) , and NIH 3T3 cells were either mock infected or infected with 10 4 particles/ cell of cesium chloride density gradient-purified recombinant vCMVp-lacZ vector for 2 h at 37°C, following which cells were treated with 0.05% trypsin and washed extensively with phosphate-buffered saline (PBS) to remove any virus particles adsorbed to cellular receptors in the plasma membrane, and low-M r DNA samples were isolated. Equivalent amounts were analyzed on Southern blots with a 32 P-labeled DNA probe specific for lacZ gene sequences as previously described (19, 24) . These data suggest that AAV does indeed gain entry into NIH 3T3 cells. The apparent lack of transgene expression in NIH 3T3 cells noted previously (24) was not due to the inactivity of the CMV promoter, since abundant expression of the lacZ gene could be detected in plasmid DNA transfection experiments (data not shown).
Although treatment of NIH 3T3 cells with tyrphostin 1, a specific inhibitor of EGFR-PTK (16), led to dephosphorylation of the ssD-BP as determined by electrophoretic mobility shift assays (EMSAs), transgene expression in tyrphostin 1-treated NIH 3T3 cells could not be detected by a cytochemical staining method (24) . EMSAs were performed as previously described (16, 25) . Briefly, 10 g of each whole-cell extract was preincubated with 2 g of poly(dI-dC), 2 g of bovine serum albumin (BSA), and 12% glycerol in HEPES buffer (pH 7.9) for 10 min at 25°C. Following preincubation, 10,000 cpm of 32 P-labeled D(Ϫ) sequence synthetic oligonucleotide (5Ј-AGGAACCCCT AGTGATGGAG-3Ј) was added to the reaction mixture and incubated for 30 min at 25°C. The bound complexes were separated from the free probe by electrophoresis on 4% polyacrylamide gels. The ratio of dephosphorylated to phosphorylated forms of ssD-BP was determined by densitometric scanning of autoradiograms with a Digital Imaging System Alphaimager (Alpha Innotech Corp., San Leandro, Calif.). These results are shown in (10 4 particles/cell), trypsinized, and washed extensively, and low-M r DNA samples were isolated and analyzed with the 32 P-labeled lacZ DNA probe as described previously (19, 24) . ssDNA, viral single-stranded DNA genomes. (B) EMSA for detection of the phosphorylation status of the ssD-BP in NIH 3T3 cells. Equivalent numbers of cells were either mock treated or treated with the indicated amounts of tyrphostin 1 at 37°C for 2 h. Whole-cell extracts were prepared and used in EMSAs with the 32 P-labeled single-stranded AAV DNA probe, as described previously (16, 25) . Phosphorylated and dephosphorylated forms of the ssD-BP are denoted by the arrow and the arrowhead, respectively. (C) AAV-mediated transgene expression. Equivalent numbers of HeLa (left) and NIH 3T3 (right) cells were infected with 5 ϫ 10 3 particles/cell of vCMVp-lacZ and then treated with the indicated amounts of tyrphostin 1 for 2 h under identical conditions. Forty-eight hours postinfection, ␤-galactosidase activity was determined as described in the text.
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NOTES 993 ment has previously been shown to significantly augment AAV-mediated transgene expression in these cells by decreasing the ratio of phosphorylated to dephosphorylated forms of ssD-BP (16) . Whereas there was a dose-dependent increase in AAV transduction efficiency in both cell types, the extent of transgene expression was roughly 2 orders of magnitude lower in NIH 3T3 cells. These results corroborate that AAV does indeed enter the NIH 3T3 cells. Entry of the virus into NIH 3T3 cells was further confirmed with AAV that was fluorescently labeled with Cy3 (Amersham Life Sciences, Pittsburgh, Pa.) as described previously (2) . 293 and NIH 3T3 cells were plated onto polylysine-treated coverslips and 24 h later were infected at 37°C with 10 4 particles per cell of Cy3-labeled AAV in medium containing 0.1% BSA. At various time points, cells were washed three times with medium containing 0.1% BSA and fixed at 4°C for 20 min with PBS containing 2% formaldehyde and 0.2% glutaraldehyde. Cellular nucleic acid was subsequently counterstained with 1 M Syto-16 (Molecular Probes, Inc., Eugene, Oreg.) for 30 min at 25°C. Cells were then washed three times with PBS, mounted on glass slides, and visualized with a Zeiss LSM 510 confocal microscope. A series of 0.3-m optical sections were made through the cells and images representative of the center of the cells were compared to assess the localization of viral particles. These results are shown in Fig. 2 . It is evident that within 15 min, AAV could bind efficiently to both 293 (Fig. 2,  panel 1 ) and NIH 3T3 (panel 3) cells. By 2 h, entry of AAV into 293 (panel 2) and NIH 3T3 (panel 4) cells was also clearly seen. As expected, M07e cells, known not to bind AAV due to lack of expression of one of the coreceptors (16, 21, 24) , failed to bind the fluorescent-labeled virus (data not shown).
Since these data are more qualitative than quantitative and do not take into account the kinetics of intracellular trafficking and uncoating of AAV in the two cell types being compared, we hypothesized that despite successful entry, a significant fraction of AAV vectors fails to enter the nucleus in NIH 3T3 cells. This hypothesis was experimentally tested as follows. Southern blot analyses of low-M r DNA isolated at various times postinfection were carried out with cytoplasmic as well as nuclear fractions isolated from 293 and NIH 3T3 cells infected under identical conditions with the CMVp-lacZ vector (10 4 particles/cell) as described above. Nuclear and cytoplasmic fractions were prepared as described previously (32) from equivalent numbers of cells, followed by isolation of low-M r DNA. These results are shown in Fig. 3A . It is evident that within 2 h, a substantial amount (ϳ76%) of the input singlestranded AAV DNA is present in the nucleus in 293 cells, whereas essentially all (ϳ99%) of the signal is detected in the cytoplasm in NIH 3T3 cells, as determined by densitometric scanning of autoradiographs. By 48 h, a small portion (ϳ18%) of the input AAV DNA does enter the nucleus in NIH 3T3 cells, but the majority (ϳ82%) of the signal is still in the cytoplasm. In contrast, ϳ78% of the input viral DNA is in the nucleus, and ϳ22% of the signal is in the cytoplasm of 293 cells 48 h postinfection. The purity of each fraction was determined to be Ͼ95%, as measured by the absence of acid phosphatase activity (in the nuclear fraction) and the absence of histone H3 (in the cytoplasmic fraction), by Western blot analysis with ␣H3 antibody (Upstate Biotechnology, Lake Placid, N.Y.) (data not shown).
We have previously reported that while AAV binds to HeLa and KB cells more efficiently than to 293 cells, AAV-mediated transduction of HeLa and KB cells is significantly lower than that of 293 cells (23) . Therefore, we compared the efficiency of AAV trafficking into the nucleus of these three cell types. These results are shown in Fig. 3B . It is clear that despite less-efficient binding, the extent of AAV entry as well as trafficking into the nucleus in 293 cells is significantly higher than that in HeLa and KB cells. Thus, in addition to the phosphorylation status of the cellular ssD-BP (23), AAV transduction efficiency among permissive human cells also correlates well with the extent of viral trafficking into the nucleus. Taken together, these studies establish that efficient translocation to the nucleus is essential for successful transduction of cells by AAV vectors.
It is interesting to note that although AAV transduction efficiency of murine cells in general has been reported to be low (18) , the exceptions include the muscle and the brain tissues (10, 12, 17, 41) . We have previously suggested that this might be due to overabundant expression of fibroblast growth factor receptor 1, a coreceptor for AAV infection (24) , and the lack of expression of the EGFR, PTK activity of which catalyzes the phosphorylation of the ssD-BP, resulting in failure to synthesize the viral second-strand DNA (16) . It would be of interest to now examine the kinetics of AAV trafficking into the nucleus in primary murine cells as well as human cells that are transduced differentially by AAV vectors, to substantiate the observations reported here. Indeed, our recent studies suggest that impaired intracellular trafficking of AAV into the nucleus in primary murine hematopoietic progenitor cells limits high-efficiency transduction of these cells, both in vitro and in vivo (39) .
Virtually nothing is known about the intracellular trafficking of AAV particles following infection. However, a wealth of information is available on the underlying mechanisms of cytoplasmic transport and nuclear import of other viruses (11) . For instance, herpesvirus binds to the cellular protein, dynein, a minus-end-directed motor protein, which transports the viral particle along microtubules toward the nucleus where the viral DNA is released through the nuclear pore complex into the nucleus (29) . Adenovirus, on the other hand, first enters the endosomal pathway and, after acidification of the endosome, is released into the cytoplasm where it appears to bind microtubules prior to nuclear entry (38) . Since both herpesviruses and adenoviruses provide the helper function for a productive infection by AAV (3, 18) and since both adenovirus and AAV use ␣V␤5 integrin as a coreceptor (36) , it is reasonable to suggest that trafficking of AAV into the nucleus might be accomplished by similar mechanisms as those employed by its helper viruses. Thus, further studies on the mechanisms of postreceptor entry, transport into the nucleus, and uncoating of AAV should allow a clearer understanding of molecular events involved in AAV-mediated high-efficiency transduction which, in turn, should lead to improvements in the optimal use of AAV vectors in human gene therapy.
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This research was supported in part by Public Health Service grants (HL-53586, HL-58881, and DK-49218; Centers of Excellence in Molecular Hematology) from the National Institutes of Health and a grant from the Phi Beta Psi Sorority. particles/cell), trypsinized, and washed extensively. Low-M r DNA samples were isolated at various indicated time points from purified nuclear (Nuc.) and cytoplasmic (Cyt.) fractions and analyzed with the 32 P-labeled lacZ DNA probe as described in the legend to Fig. 1. (B) Southern blot analyses of AAV entry and trafficking into the nucleus of permissive human cell lines. Equivalent numbers of HeLa, KB, and 293 cells were infected with the recombinant vCMVp-lacZ vector, trypsinized, and washed extensively, and low-M r DNA samples were isolated 2 h postinfection from purified nuclear and cytoplasmic fractions. The rest of the analysis on Southern blots was performed as described above.
